FDA issues complete response letter to Disc Medicine’s bitopertin NDA
The AURORA and BEACON studies demonstrated that bitopertin significantly reduces whole blood metal-free PPIX.
Drug Development
Immunic secures $400m fund to support commercial-stage development
Ampersand Capital acquires Purna Pharmaceuticals
Amgen receives EC approval for Uplizna in generalised myasthenia gravis
Citius Oncology and Uniphar sign European distribution deal for Lymphir
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
THX Pharma and Biocodex sign licensing deal for Batten-1 and TX01 drugs
Insilico and CMS launch drug discovery collaborations for CNS diseases
